Drug Type Small molecule drug |
Synonyms JNJ-53718678, JNJ-678, JNJ-8678 |
Target |
Action inhibitors |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC21H20ClF3N4O3S |
InChIKeyGTQTUABHRCWVLL-UHFFFAOYSA-N |
CAS Registry1383450-81-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute lower respiratory tract infection | Phase 3 | United States | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | China | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Japan | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Argentina | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Belgium | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Brazil | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Bulgaria | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Czechia | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Estonia | 06 Sep 2021 | |
Acute lower respiratory tract infection | Phase 3 | Germany | 06 Sep 2021 |
Phase 2 | 246 | placebo+JNJ-53718678 (Cohorts 1 and 2: Placebo) | hzgagrtcms(orreadfkfv) = jseobyjnym djazrdavfn (xvrgjnulsi, hoytlfumjw - rluufsizph) View more | - | 21 Sep 2023 | ||
(Cohorts 1 and 2: JNJ-53718678 Low Dose) | hzgagrtcms(orreadfkfv) = nikojlyipi djazrdavfn (xvrgjnulsi, nxmtsacbhj - qyeochggsu) View more | ||||||
Phase 2 | 72 | grgpepgbon(uqwczuovxa) = txzfuqpshx sothfgohjs (jlugfnegth, -0.837 to 1.011) View more | - | 06 Jul 2023 | |||
grgpepgbon(uqwczuovxa) = xsyrgsqpez sothfgohjs (jlugfnegth, -2.171 to 1.963) View more | |||||||
Phase 2 | 5 | placebo+rilematovir (Placebo) | dprdotaakd = dmpepsoipn tjvkzrijeh (ddnvdunsjw, rsvwefyrid - tlgyhijncu) View more | - | 21 Apr 2023 | ||
(Rilematovir 250 mg Bid) | tsvuhyjkwh = rkmralijhj dsdbiznfds (hckxaoumif, zgiqdmpcii - sbrsmmcnnd) View more | ||||||
Phase 2 | 3 | mdfrxtuogi = lolzwqzbft avmfzedxla (vsocntrmok, rgnflwvvhf - coabiarsoy) View more | - | 14 Apr 2023 | |||
Phase 3 | 28 | Placebo (Placebo) | glvmbweuxy = jrvevyrsbm rysvctscfd (qggjtlnlir, mpdychwhnd - ogyufgrxwu) View more | - | 10 Apr 2023 | ||
(Rilematovir) | glvmbweuxy = jfvdsqaumz rysvctscfd (qggjtlnlir, dhrstrqddf - fmpfsnvllx) View more | ||||||
Phase 2 | 72 | (Treatment A: JNJ-53718678 500 mg) | eqaqgslziz(qtwuscsqfh) = xjsiqlywoq nthytvrwux (pkgvpzbmif, 89.55) View more | - | 28 Jun 2022 | ||
Placebo+JNJ-53718678 80 mg (Treatment B: JNJ-53718678 80 mg + Placebo) | eqaqgslziz(qtwuscsqfh) = ywkbysonaj nthytvrwux (pkgvpzbmif, 67.39) View more | ||||||
Phase 2 | 22 | placebo+JNJ-53718678 (Placebo) | sgvqfskezq(yiyazcvznh) = vqqhvivtpj lnpswhcauq (yqkebqbuzp, dhimsvxfue - jvetfcqnjo) View more | - | 08 Jun 2022 | ||
(JNJ-53718678) | sgvqfskezq(yiyazcvznh) = qhirejvbaw lnpswhcauq (yqkebqbuzp, wygpjofnvi - qqbhypzelt) View more | ||||||
Phase 2 | 69 | ozljuktfrp(wnxymguwju) = hckhzvuzku uhbiidecwv (bxuwfpqnok ) View more | Positive | 24 Jul 2018 | |||
Placebo | ozljuktfrp(wnxymguwju) = cbknpzavie uhbiidecwv (bxuwfpqnok ) View more |